Top Page
Terragen Holdings Ltd
(Sydney:TGH)
Terragen Holdings Ltd (TGH) vs. iShares MSCI Australia ETF (EWA)
Terragen Holdings Ltd Business Overview & Revenue Model
Terragen Holdings Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.62M | 1.62M | 2.14M | 3.28M | 2.89M | 3.65M |
| Gross Profit | 792.23K | 792.23K | 2.06M | 3.21M | 2.62M | 3.19M |
| EBITDA | -4.70M | -4.68M | -3.50M | -3.46M | -5.67M | -6.13M |
| Net Income | -3.72M | -3.72M | -3.01M | -3.23M | -5.41M | -6.10M |
Balance Sheet | ||||||
| Total Assets | 8.12M | 8.12M | 6.95M | 6.35M | 9.22M | 14.72M |
| Cash, Cash Equivalents and Short-Term Investments | 4.81M | 4.81M | 4.54M | 4.17M | 6.67M | 11.64M |
| Total Debt | 735.45K | 735.45K | 542.23K | 239.37K | 332.26K | 357.96K |
| Total Liabilities | 1.55M | 1.55M | 1.63M | 1.27M | 1.46M | 1.70M |
| Stockholders Equity | 6.57M | 6.57M | 5.32M | 5.08M | 7.76M | 13.02M |
Cash Flow | ||||||
| Free Cash Flow | -3.03M | -3.03M | -2.35M | -2.91M | -4.97M | -4.93M |
| Operating Cash Flow | -3.03M | -3.03M | -2.32M | -2.81M | -4.80M | -4.52M |
| Investing Cash Flow | -682.43K | -682.43K | -132.93K | -35.20K | -118.20K | -408.02K |
| Financing Cash Flow | 3.87M | 3.87M | 2.82M | 351.00K | -52.70K | 194.92K |
Terragen Holdings Ltd Technical Analysis
Terragen Holdings Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
49 Neutral | AU$31.38M | -14.26 | -41.21% | ― | 140.94% | 88.59% | |
46 Neutral | AU$12.12M | -2.70 | -62.66% | ― | -24.42% | -2.30% | |
46 Neutral | AU$10.40M | -1.09 | -390.08% | ― | ― | 19.94% | |
43 Neutral | AU$25.04M | -5.95 | -25.50% | ― | -100.00% | -182.93% | |
26 Underperform | AU$6.49M | -1.15 | -217.79% | ― | ― | 43.46% |
Terragen Holdings Ltd Corporate Events
Terragen Holdings Limited has received a $989,242 R&D tax incentive from the Australian Taxation Office for the 2024/2025 financial year, which will bolster their cash reserves and support ongoing commercialisation and development efforts. This incentive underscores Terragen’s commitment to advancing its position in the agricultural industry by investing in innovative solutions that enhance productivity and environmental outcomes, benefiting stakeholders and contributing to agricultural decarbonisation.
Terragen Holdings Limited has updated its Securities Trading Policy to align with Listing Rule 12.10, reflecting good corporate governance practices. The revisions include clearer guidelines for employee access to sensitive information, updated closed periods to coincide with the release of the Appendix 4C report, and the inclusion of the Chairman in the prior notification clause. These changes are part of Terragen’s commitment to maintaining transparency and compliance, potentially impacting how stakeholders interact with the company’s securities.
Terragen Holdings Limited held its Annual General Meeting on November 20, 2025, where all resolutions were successfully passed. Key resolutions included the adoption of the remuneration report, election of Mike Barry as a director, approval of securities issuance under the incentive plan, ratification of prior employee options issuance, approval of an additional 10% placement facility, and the appointment of an auditor. These decisions reflect the company’s strategic focus on strengthening its governance and financial structure, potentially enhancing its market position and stakeholder confidence.
Terragen Holdings Limited presented a summary of its current activities and financial data, emphasizing its diversified portfolio in animal probiotics and biostimulants. The presentation, intended for informational purposes, highlighted the company’s strategic positioning in the biotechnology sector, although it did not serve as an investment offer or advice. Stakeholders are advised to consider the inherent risks and uncertainties associated with forward-looking statements contained in the presentation.
Terragen Holdings Limited has released an investor update highlighting its current activities and market positioning. The update emphasizes the company’s commitment to advancing its biotechnology offerings, particularly in animal probiotics and biostimulants, which are crucial for sustainable agriculture. While the presentation includes forward-looking statements, it primarily serves as an informational document rather than an investment guide.
Terragen Holdings Limited has announced a significant purchase order from Mort & Co Fertilisers for 70,000 litres of its Great Land Plus bio-stimulant, following successful product trials. This order is expected to boost Terragen’s GLP sales by 57% in 2026, with an estimated annual revenue of $700,000, reflecting the product’s alignment with sustainability and productivity goals in the agricultural sector.
Terragen Holdings Limited has announced its upcoming Annual General Meeting, which will be held virtually on November 20, 2025. The meeting will provide shareholders with the opportunity to participate and vote online, ensuring accessibility and engagement. This event is crucial for stakeholders to discuss the company’s future strategies and operational plans, potentially impacting its market positioning and shareholder interests.
Terragen Holdings Limited has announced a change in its external auditor, transitioning from SW Audit to MVAB Assurance, pending shareholder approval at the upcoming Annual General Meeting. This change, effective from November 20, 2025, is part of Terragen’s ongoing efforts to ensure robust financial oversight and aligns with regulatory requirements, potentially impacting its operational transparency and stakeholder confidence.
Terragen Holdings Limited announced that its 2025 Annual General Meeting will be held on November 20, 2025. The company also noted that nominations for director elections must be submitted by October 3, 2025. This announcement is significant as it outlines the company’s governance and strategic planning processes, which are crucial for stakeholders and investors. The upcoming meeting and director nominations could influence the company’s future direction and industry positioning.
Terragen Holdings Ltd has released its corporate governance statement for the period from 1 July 2024 to 30 June 2025, detailing its compliance with the ASX Corporate Governance Council’s Fourth Edition Principles and Recommendations. The statement highlights the adoption of a formal board charter that outlines the roles and responsibilities of the board and management, emphasizing leadership, strategic objectives, and risk management. This announcement underscores Terragen’s commitment to maintaining high governance standards, which is crucial for its operational integrity and stakeholder trust.
Terragen Holdings Limited has announced the issuance of 1,500,000 unquoted share options with an exercise price of $0.11, as part of an employee incentive scheme. This move is aimed at enhancing employee engagement and retention, potentially impacting the company’s operational dynamics and market positioning positively.
Terragen Holdings Limited announced the issuance of 1,500,000 unquoted share options with an exercise price of $0.085 as part of an employee incentive scheme. This move is expected to enhance employee engagement and align their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and market positioning.
Terragen Holdings Limited announced the issuance of 1,500,000 share options at an exercise price of $0.06 as part of an employee incentive scheme. This move is aimed at enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and market positioning positively.
Terragen Holdings Limited has announced the issuance of 1,500,000 unquoted share options with an exercise price of $0.025, as part of an employee incentive scheme. This move is likely aimed at motivating employees and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and market positioning.
Terragen Holdings Limited reported a transformative year in 2025, overcoming drought challenges with resilience and focusing on growth. The company launched new probiotics for ruminants, expanded its crop solutions portfolio, and progressed international regulatory submissions. A US patent granted in July 2025 bolsters its North American expansion. Terragen aims to expand its market presence in animal nutrition and crop solutions, supported by investor confidence and scientific validation, to drive financial stability and sustainable farming practices.